Molika Ashford
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.

Articles Authored by Molika Ashford
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
Oxford Team Debuts Multi-Modal MCED Approach Built on Exact Sciences Methylation Sequencing Tech
Premium
The group's TriOx assay sensitively detected cancers, including at early stages, using combined sequencing of methylation and gene alterations.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment.

Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.

The McGill University team is advancing a test, dubbed DOvEEgene, which sequences DNA from a uterine brush sample to detect cancer-associated mutations.
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
